What did Jefferies change in the DYN analyst rating on March 9, 2026?

Jefferies maintained a **Buy** on Dyne Therapeutics on March 9, 2026, citing **70-80%+** confidence in accelerated approval by **Q1:27** and did not issue a new price target.

Does the maintained DYN analyst rating include a new price target?

No. The Jefferies note maintained a **Buy** but did not publish a new DYN price target, leaving consensus targets unchanged for now and keeping valuation debates open.

How should investors use the DYN analyst rating in decision making?

Treat the DYN analyst rating as a sentiment signal tied to regulatory odds. Combine it with your risk tolerance, trial data, and valuation scenarios before acting on any position changes.

What are the main catalysts tied to the DYN analyst rating?

Primary catalysts include FDA communications, accelerated approval timelines, confirmatory study results, and company updates on development milestones tied to the regulatory path.

Analyst Ratings

Jefferies Maintains Buy on Dyne Therapeutics (DYN) March 2026

ByHuzaifa Zahoor March 10, 2026

Jefferies maintained a Buy on Dyne Therapeutics, Inc. (DYN) on March 9, 2026. The DYN analyst rating underscores Jefferies’ 70-80%+ confidence in an accelerated approval by Q1:27. Jefferies did not publish a fresh price target in this note. The rating action coincided with a 5.14% ($0.87) price move since the note’s timestamp. Meyka AI’s real-time tracking flags this as a stability signal from a major biotech analyst.